Ventana Medical’s HPV Claims Probed By FDA In Vitro Diagnostic Office
This article was originally published in The Gray Sheet
Executive Summary
Ventana Medical contends that its Inform HPV in-situ hybridization (ISH) probes qualify as analyte-specific reagents and do not require premarket notification, despite FDA's assertions to the contrary
You may also be interested in...
FDA, Agendia To Determine Scope Of MammaPrint Premarket Regulation
Agendia's MammaPrint breast cancer recurrence assay may qualify for a CLIA waiver and require no further premarket regulation, the company says
FDA, Agendia To Determine Scope Of MammaPrint Premarket Regulation
Agendia's MammaPrint breast cancer recurrence assay may qualify for a CLIA waiver and require no further premarket regulation, the company says
Roche Outlines ASR, Microarray Changes Made In Response To FDA Letter
Roche Diagnostic microarrays will be sold as research-use only tests until the firm is able to seek in vitro diagnostic status, Robert Gregg, PhD, director of regulatory submissions, explained during the American Association of Clinical Chemistry annual meeting in Los Angeles July 26